Skip to main content
Quest Diagnostics

Assess cardiometabolic disease with 1 panel

Cardiometabolic disease describes the interplay between risk factors for interrelated disorders that affect cardiovascular and metabolic health. These include cardiovascular disease, glycemic control (prediabetes or type 2 diabetes [T2D]), chronic kidney disease (CKD), metabolic dysfunction-associated steatotic liver disease (MASLD), and common endocrine disorders, which share cardiometabolic risk factors.

One panel can now be used to simplify the testing approach for early identification, empower accurate diagnosis, and help improve outcomes of interrelated chronic cardiometabolic conditions.

In this article:

Clinical challenge | Why it matters | Ordering recommendations | Interpreting test results | Next steps | Supporting resources

Clinical challenge: Rising prevalence of cardiometabolic conditions

Cardiometabolic disease starts differently in every patient, with early stages being clinically silent. Primary care providers need a streamlined way to identify high-risk patients.

Patients most at risk of cardiometabolic disease who should be considered for assessment include

  • Individuals at risk of metabolic dysfunction (eg, individuals >45 years [male], >50 years [female], with family history of CVD and/or with sedentary lifestyle)
  • Individuals at risk of insulin resistance (IR), which can lead to prediabetes or T2D (eg, individuals who are overweight/obese [BMI >25, waist circumference >35 inches, women; >40 inches, men], have a family history of diabetes, have a history of gestational diabetes, or have acanthosis nigricans)
  • Individuals with an HbA1c ≥5.0%
  • Individuals with a history of hypertension
  • Individuals with endocrine disease (hypothyroidism, primary aldosteronism (PA), hypogonadism/low testosterone [low T], or PCOS)
  • Individuals with liver (MASLD) or kidney (CKD) disease

Estimated prevalence of cardiometabolic conditions in the US

38.4M

have type 2 diabetes1

127.9M

have cardiovascular disease2

35.5M

have chronic kidney disease3

100M

have MASLD4

Why it matters: Improved patient outcomes

Testing at-risk individuals and early diagnosis significantly improve patient outcomes by enabling timely intervention, targeted management and treatment strategies, and decreased risk

of disease progression. Identifying conditions before they become overt disease can reduce overall healthcare costs.

Several medical organizations align on the importance of diagnostic testing for cardiovascular disease, prediabetes or type 2 diabetes, CKD, MASLD, and common endocrine disorders. The American Heart Association®,5 American Association of Clinical Endocrinology®, and the National Kidney Foundation® each recognize and advocate for early risk identification and early diagnosis of interrelated cardiometabolic conditions.

Cardiometabolic disease ordering recommendations: 7 tests, 1 panel

Quest Diagnostics developed the Cardiometabolic Disease Assessment (CMDA) Panel, a comprehensive approach to identifying and quantifying the presence of cardiometabolic disease across multiple interrelated organ systems. From HbA1c and insulin resistance testing to common endocrine disorder testing, the CMDA Panel combines 7 tests under a single test code.

Recommended tests for cardiometabolic disease

Cardiometabolic Disease Assessment (CMDA) Panel

  • Test code: 14273
  • CPT codes: 80061*, 82172*, 83036*, 83525, 84681, 82570, 82043, 80053, 85049*, 84443*
    *CPT® code is subject to a Medicare Limited Coverage Policy and may require a signed ABN when ordering.

Breakdown of the CMDA Panel

The tests within the CMDA Panel include

  • Cardio IQ® Hemoglobin A1c (91732)
  • Cardio IQ® Insulin Resistance Panel with Score (36509)
    • Includes Insulin, Intact LC/MS/MS (93103), C-peptide, and calculated IR score
  • Cardio IQ® Apolipoprotein B (91726)
  • Lipid Panel, Cardio IQ
    • Includes total cholesterol (91717), triglycerides (91718), HDL-C (91719), calculated LDL-C cholesterol/HDL ratio, non-HDL-C, and Cardio IQ interpretative report
  • TSH (899)
  • Kidney Profile (39165)
    • Includes albumin, random urine with creatinine (6517), and serum creatinine (375) with calculated eGFR
  • Comprehensive Metabolic Panel with Fibrosis-4 (FIB-4) Index (10372)
    • Includes albumin (233), albumin/globulin ratio (calculated) alkaline phosphatase (234), ALT (823), AST (822), BUN/creatinine ratio (296), calcium (303), carbon dioxide (310), chloride (330), creatinine with eGFR (375), globulin (calculated), glucose (483), potassium (733), sodium (836), total bilirubin (287), total protein (754), urea nitrogen (294), platelet count (723), and FIB-4 index (calculated)

Panel components may also be ordered individually.

 

Enhanced report for interpreting test results

Quest’s enhanced CMDA Panel report helps providers identify cardiometabolic disease with ease. Each section of the report uses color-coded visuals to illustrate whether the results of each panel component are in or out of normal range, as well as historical values to determine how those test results are trending. The report comprehensively enables a patient’s care team to identify the presence of cardiometabolic disease, evaluate its progression over time, and follow up on progress.

 

A: Test groupings
Lipid, glycemic, endocrine, kidney, and liver tests assess the presence of cardiometabolic disease and its subsequent impacts across each organ system.

B: Actionable results
Results from many of the test components, such as lipids, HbA1c, eGFR, and uACR align with publicly available health calculators and guidelines, such as PREVENT™.

C: Color-coded key
The report uses green, yellow, and red color coding to visually depict whether the patient’s relative risk or results are in or out of the optimal reference ranges.

D: Historical trends
An easy-to-read view of results from prior visits allows providers to assess trends over time, including impact from recent lifestyle or treatment modifications.

E: Significant results
Graphics that visually interpret significant test results help providers assess impacts of insulin resistance, CKD, and liver disease.

F: Monitor progress
An at-a-glance summary of CMDA Panel results throughout the patient’s health journey shows if their cardiometabolic disease is progressing and whether further testing or treatment is required.

Next steps: Monitor and assess cardiometabolic disease

Patients with risk factors should be assessed annually. The results of each yearly test will guide providers to next steps, including appropriate follow-up tests, creating a lifestyle modification plan, and/or treatment to manage chronic conditions.

 

Supporting resources

CMDA Panel web page
Test overview brochure
Enhanced report overview
Cardiometabolic Clinical Approach Detailed Brochure
CDMA Panel test summary

Bridge the gap between chronic cardiometabolic conditions

Ready to learn more about Quest’s streamlined, comprehensive solution for cardiometabolic disease assessment?

Contact us

Clinical Education Center resources

Pathology & Laboratory Medicine
Audio Podcast
Instant Insights: Streamlining Cardiometabolic Disease Assessment
Audio Podcast
The Cardiometabolic Approach: A Solution to Modern Disease Risk Assessment
Pathology & Laboratory Medicine
Audio Podcast
The Insulin Resistance Revolution: The Key to Preventing Chronic Conditions
Health & Wellness
Audio Podcast
Instant Insights: Apolipoprotein B
Pathology & Laboratory Medicine
Audio Podcast
Instant Insight: Kidney Profile and Cystatin C
View all articles

References

1. CDC. National Diabetes Statistics Report. Published May 15, 2024. Accessed November 19, 2025. https://www.cdc.gov/diabetes/php/data-research/index.html

2. American Heart Association. 2024 heart disease and stroke statistics update fact sheet. Published 2024. Accessed November 19, 2025. https://www.heart.org/-/media/PHD-Files-2/Science-News/2/2024-Heart-and-Stroke-Stat-Update/2024-Statistics-At-A-Glance-final_2024.pdf

3. CDC. Chronic kidney disease in the United States, 2023. https://cdc.gov/kidney-disease/php/data-research/?CDC_AAref_Val=https://cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html

4. American Liver Foundation. Metabolic dysfunction-associated steatotic liver disease (MASLD). Updated September 25, 2025. Accessed November 19, 2025. https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-fatty-liver-disease-nafld/

5. Sasson C, Eckel R, Alger H, et al. American Heart Association Diabetes and Cardiometabolic Health Summit: Summary and Recommendations. J Am Heart Assoc. 2018;7(15):e009271. doi:10.1161/JAHA.118.009271

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.